{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:53:54Z","timestamp":1781643234892,"version":"3.54.5"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T00:00:00Z","timestamp":1773532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":44,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Grant-in-Aid for Scientific Research","award":["22K07172"],"award-info":[{"award-number":["22K07172"]}]},{"DOI":"10.13039\/100008702","name":"Kagoshima University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008702","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Achieving both selectivity and cytotoxicity against cancer cells remains a major challenge in cancer therapy. Histone deacetylase (HDAC) inhibitors, such as tucidinostat, suppress tumor growth by epigenetically regulating tumor suppressor gene expression and are approved for the treatment of hematological malignancies. Despite their promising efficacy, frequent and severe adverse effects, particularly hematological toxicities, often limit long-term treatment, underscoring the urgent need for safer therapeutic strategies. In this study, we show ex vivo that combining tucidinostat with dipyridamole, an approved antiplatelet agent and equilibrative nucleoside transporter (ENT) inhibitor, reduces the effective dose of tucidinostat while maintaining its antitumor activity. In ex vivo models, this combination exerted specific and potent effects against T-cell lymphomas, including adult T-cell leukemia\/lymphoma (ATL), inducing apoptosis beyond that achieved with either agent alone. Mechanistically, ENT inhibition appeared to enhance extracellular adenosine signaling, and activation of adenosine receptors, particularly A2b, contributed, at least in part, to the observed antitumor synergy. Moreover, tucidinostat-mediated HDAC inhibition was associated with upregulation of genes involved in adenosine signaling, including adenosine receptors as well as CD39 and CD73, suggesting a coordinated molecular mechanism underlying the enhanced efficacy. Collectively, these findings suggest that the combination of tucidinostat and dipyridamole may represent a promising therapeutic approach targeting both epigenetic and metabolic pathways to enhance cancer cell death in hematological malignancies.<\/jats:p>","DOI":"10.1038\/s41598-026-43642-1","type":"journal-article","created":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T06:33:41Z","timestamp":1773556421000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Synergistic effects of HDAC inhibitor tucidinostat and ENT inhibitor dipyridamole in T-cell malignancies"],"prefix":"10.1038","volume":"16","author":[{"given":"Jiazhou","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed E.","family":"Goda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Enriquez-Vera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satomi","family":"Harazono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jhajaira M.","family":"Araujo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nao","family":"Nishikoba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Velarde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atakan Zeki","family":"Namli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro De Jesus","family":"Huamani Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Nakahata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,15]]},"reference":[{"key":"43642_CR1","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1056\/NEJMra1805035","volume":"383","author":"SE Bates","year":"2020","unstructured":"Bates, S. E. Epigenetic Therapies for Cancer. N. Engl. J. Med. 383, 650\u2013663. https:\/\/doi.org\/10.1056\/NEJMra1805035 (2020).","journal-title":"N. Engl. J. Med."},{"key":"43642_CR2","doi-asserted-by":"publisher","first-page":"932914","DOI":"10.3389\/fphar.2022.932914","volume":"13","author":"Y Sun","year":"2022","unstructured":"Sun, Y. et al. Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment. Front. Pharmacol. 13, 932914. https:\/\/doi.org\/10.3389\/fphar.2022.932914 (2022).","journal-title":"Front. Pharmacol."},{"key":"43642_CR3","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1093\/jjco\/hyac086","volume":"52","author":"M Yoshimitsu","year":"2022","unstructured":"Yoshimitsu, M. et al. Oral histone deacetylase inhibitor HBI-8000 (tucidinostat) in Japanese patients with relapsed or refractory non-Hodgkin\u2019s lymphoma: phase I safety and efficacy. Jpn. J. Clin. Oncol. 52, 1014\u20131020. https:\/\/doi.org\/10.1093\/jjco\/hyac086 (2022).","journal-title":"Jpn. J. Clin. Oncol."},{"key":"43642_CR4","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1111\/cas.15431","volume":"113","author":"A Utsunomiya","year":"2022","unstructured":"Utsunomiya, A. et al. Oral histone deacetylase inhibitor tucidinostat (HBI-8000) in patients with relapsed or refractory adult T-cell leukemia\/lymphoma: Phase IIb results. Cancer Sci. 113, 2778\u20132787. https:\/\/doi.org\/10.1111\/cas.15431 (2022).","journal-title":"Cancer Sci."},{"key":"43642_CR5","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s12185-025-03963-9","volume":"122","author":"A Kamiunten","year":"2025","unstructured":"Kamiunten, A. et al. Effects of tucidinostat in adult T-cell leukemia\/lymphoma in clinical practice. Int. J. Hematol. 122, 83\u201392. https:\/\/doi.org\/10.1007\/s12185-025-03963-9 (2025).","journal-title":"Int. J. Hematol."},{"key":"43642_CR6","doi-asserted-by":"publisher","first-page":"1415597","DOI":"10.3389\/fimmu.2024.1415597","volume":"15","author":"J Hu","year":"2024","unstructured":"Hu, J., Wang, J. & Wang, Z. The efficacy and safety of chidamide in combination with etoposide and glucocorticoids for the treatment of hemophagocytic lymphohistiocytosis in adult patients: an open-label, single-center study. Front. Immunol. 15, 1415597. https:\/\/doi.org\/10.3389\/fimmu.2024.1415597 (2024).","journal-title":"Front. Immunol."},{"key":"43642_CR7","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13045-024-01624-8","volume":"17","author":"J Lin","year":"2024","unstructured":"Lin, J. et al. Tucidinostat plus pediatric-inspired chemotherapy for newly diagnosed adult ETP-ALL\/LBL: a single-arm, phase 2 trial. J. Hematol. Oncol. 17, 101. https:\/\/doi.org\/10.1186\/s13045-024-01624-8 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"43642_CR8","doi-asserted-by":"publisher","first-page":"e70919","DOI":"10.1002\/cam4.70919","volume":"14","author":"Q Zou","year":"2025","unstructured":"Zou, Q. et al. Chidamide, a Histone Deacetylase Inhibitor, Combined With R-GemOx in Relapsed\/Refractory Diffuse Large B-Cell Lymphoma (TRUST): A Multicenter, Single-Arm, Phase 2 Trial. Cancer Med. 14, e70919. https:\/\/doi.org\/10.1002\/cam4.70919 (2025).","journal-title":"Cancer Med."},{"key":"43642_CR9","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1186\/s12916-022-02598-5","volume":"20","author":"P Zhang","year":"2022","unstructured":"Zhang, P. et al. Optimized dose selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumors. BMC Med. 20, 435. https:\/\/doi.org\/10.1186\/s12916-022-02598-5 (2022).","journal-title":"BMC Med."},{"key":"43642_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1080\/15257770.2016.1210805","volume":"36","author":"RC Boswell-Casteel","year":"2017","unstructured":"Boswell-Casteel, R. C. & Hays, F. A. Equilibrative nucleoside transporters-A review. Nucleosides Nucleotides Nucleic Acids. 36, 7\u201330. https:\/\/doi.org\/10.1080\/15257770.2016.1210805 (2017).","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"43642_CR11","doi-asserted-by":"publisher","unstructured":"Naes, S. M., Ab-Rahim, S. & Mazlan, M. & Abdul Rahman, A. Equilibrative Nucleoside Transporter 2: Properties and Physiological Roles. Biomed Res Int, (2020). https:\/\/doi.org\/10.1155\/2020\/5197626 (2020).","DOI":"10.1155\/2020\/5197626"},{"key":"43642_CR12","doi-asserted-by":"publisher","first-page":"8375","DOI":"10.1074\/jbc.275.12.8375","volume":"275","author":"JL Ward","year":"2000","unstructured":"Ward, J. L., Sherali, A., Mo, Z. P. & Tse, C. M. Kinetic and pharmacological properties of cloned human equilibrative nucleoside transporters, ENT1 and ENT2, stably expressed in nucleoside transporter-deficient PK15 cells. Ent2 exhibits a low affinity for guanosine and cytidine but a high affinity for inosine. J. Biol. Chem. 275, 8375\u20138381. https:\/\/doi.org\/10.1074\/jbc.275.12.8375 (2000).","journal-title":"J. Biol. Chem."},{"key":"43642_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.mam.2017.01.002","volume":"55","author":"MM Faas","year":"2017","unstructured":"Faas, M. M., Saez, T. & de Vos, P. Extracellular ATP and adenosine: The Yin and Yang in immune responses? Mol. Aspects Med. 55, 9\u201319. https:\/\/doi.org\/10.1016\/j.mam.2017.01.002 (2017).","journal-title":"Mol. Aspects Med."},{"key":"43642_CR14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12943-023-01733-x","volume":"22","author":"C Xia","year":"2023","unstructured":"Xia, C., Yin, S., To, K. K. W. & Fu, L. CD39\/CD73\/A2AR pathway and cancer immunotherapy. Mol. Cancer. 22, 44. https:\/\/doi.org\/10.1186\/s12943-023-01733-x (2023).","journal-title":"Mol. Cancer"},{"key":"43642_CR15","doi-asserted-by":"publisher","first-page":"627","DOI":"10.3389\/fphar.2018.00627","volume":"9","author":"M Pastor-Anglada","year":"2018","unstructured":"Pastor-Anglada, M. & Perez-Torras, S. Who Is Who in Adenosine Transport. Front. Pharmacol. 9, 627. https:\/\/doi.org\/10.3389\/fphar.2018.00627 (2018).","journal-title":"Front. Pharmacol."},{"key":"43642_CR16","doi-asserted-by":"publisher","first-page":"606","DOI":"10.3389\/fphar.2018.00606","volume":"9","author":"M Pastor-Anglada","year":"2018","unstructured":"Pastor-Anglada, M. & Perez-Torras, S. Emerging Roles of Nucleoside Transporters. Front. Pharmacol. 9, 606. https:\/\/doi.org\/10.3389\/fphar.2018.00606 (2018).","journal-title":"Front. Pharmacol."},{"key":"43642_CR17","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/nrc3613","volume":"13","author":"L Antonioli","year":"2013","unstructured":"Antonioli, L., Blandizzi, C., Pacher, P. & Hasko, G. Immunity, inflammation and cancer: a leading role for adenosine. Nat. Rev. Cancer. 13, 842\u2013857. https:\/\/doi.org\/10.1038\/nrc3613 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"43642_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.imlet.2018.04.006","volume":"205","author":"L Antonioli","year":"2019","unstructured":"Antonioli, L., Fornai, M., Blandizzi, C., Pacher, P. & Hasko, G. Adenosine signaling and the immune system: When a lot could be too much. Immunol. Lett. 205, 9\u201315. https:\/\/doi.org\/10.1016\/j.imlet.2018.04.006 (2019).","journal-title":"Immunol. Lett."},{"key":"43642_CR19","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1023\/a:1009666707307","volume":"4","author":"KA Jacobson","year":"1999","unstructured":"Jacobson, K. A., Hoffmann, C., Cattabeni, F. & Abbracchio, M. P. Adenosine-induced cell death: evidence for receptor-mediated signalling. Apoptosis 4, 197\u2013211. https:\/\/doi.org\/10.1023\/a:1009666707307 (1999).","journal-title":"Apoptosis"},{"key":"43642_CR20","doi-asserted-by":"publisher","first-page":"3390molecules29","DOI":"10.3390\/molecules29153501","volume":"10","author":"K. N. Venugopala","year":"2024","unstructured":"Venugopala, K. N. & Buccioni, M. Current understanding of the role of adenosine receptors in cancer. Molecules 10, 3390molecules29153501 https:\/\/doi.org\/10.3390\/molecules29153501 (2024).","journal-title":"Molecules"},{"key":"43642_CR21","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41375-020-0788-y","volume":"35","author":"Y Nagate","year":"2021","unstructured":"Nagate, Y. et al. Ectonucleotidase CD39 is highly expressed on ATLL cells and is responsible for their immunosuppressive function. Leukemia 35, 107\u2013118. https:\/\/doi.org\/10.1038\/s41375-020-0788-y (2021).","journal-title":"Leukemia"},{"key":"43642_CR22","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.clml.2011.06.005","volume":"11","author":"D Pulte","year":"2011","unstructured":"Pulte, D. et al. CD39 expression on T lymphocytes correlates with severity of disease in patients with chronic lymphocytic leukemia. Clin. Lymphoma Myeloma Leuk. 11, 367\u2013372. https:\/\/doi.org\/10.1016\/j.clml.2011.06.005 (2011).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"43642_CR23","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.bmcl.2008.11.112","volume":"19","author":"A Gupte","year":"2009","unstructured":"Gupte, A. & Buolamwini, J. K. Synthesis and biological evaluation of phloridzin analogs as human concentrative nucleoside transporter 3 (hCNT3) inhibitors. Bioorg. Med. Chem. Lett. 19, 917\u2013921. https:\/\/doi.org\/10.1016\/j.bmcl.2008.11.112 (2009).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"43642_CR24","doi-asserted-by":"publisher","unstructured":"Ruan, W. et al. Targeting myocardial equilibrative nucleoside transporter ENT1 provides cardioprotection by enhancing myeloid Adora2b signaling. JCI Insight. 8 https:\/\/doi.org\/10.1172\/jci.insight.166011 (2023).","DOI":"10.1172\/jci.insight.166011"},{"key":"43642_CR25","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1038\/s41590-025-02153-3","volume":"26","author":"TJ Sanders","year":"2025","unstructured":"Sanders, T. J. et al. Inhibition of ENT1 relieves intracellular adenosine-mediated T cell suppression in cancer. Nat. Immunol. 26, 854\u2013865. https:\/\/doi.org\/10.1038\/s41590-025-02153-3 (2025).","journal-title":"Nat. Immunol."},{"key":"43642_CR26","doi-asserted-by":"publisher","first-page":"10738","DOI":"10.1038\/s41467-024-54914-7","volume":"15","author":"NJ Wright","year":"2024","unstructured":"Wright, N. J. et al. Design of an equilibrative nucleoside transporter subtype 1 inhibitor for pain relief. Nat. Commun. 15, 10738. https:\/\/doi.org\/10.1038\/s41467-024-54914-7 (2024).","journal-title":"Nat. Commun."},{"key":"43642_CR27","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1097\/FJC.0000000000000194","volume":"65","author":"C Yang","year":"2015","unstructured":"Yang, C. & Leung, G. P. Equilibrative Nucleoside Transporters 1 and 4: Which One Is a Better Target for Cardioprotection Against Ischemia-Reperfusion Injury? J. Cardiovasc. Pharmacol. 65, 517\u2013521. https:\/\/doi.org\/10.1097\/FJC.0000000000000194 (2015).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"43642_CR28","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/j.bcp.2013.08.063","volume":"86","author":"C Wang","year":"2013","unstructured":"Wang, C. et al. Dipyridamole analogs as pharmacological inhibitors of equilibrative nucleoside transporters. Identification of novel potent and selective inhibitors of the adenosine transporter function of human equilibrative nucleoside transporter 4 (hENT4). Biochem. Pharmacol. 86, 1531\u20131540. https:\/\/doi.org\/10.1016\/j.bcp.2013.08.063 (2013).","journal-title":"Biochem. Pharmacol."},{"key":"43642_CR29","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10557-005-4659-6","volume":"19","author":"W Schaper","year":"2005","unstructured":"Schaper, W. Dipyridamole, an underestimated vascular protective drug. Cardiovasc. Drugs Ther. 19, 357\u2013363. https:\/\/doi.org\/10.1007\/s10557-005-4659-6 (2005).","journal-title":"Cardiovasc. Drugs Ther."},{"key":"43642_CR30","doi-asserted-by":"publisher","unstructured":"Bukoski, R. D. & Sparks, H. V. Adenosine production and release by adult rat cardiocytes. J. Mol. Cell. Cardiol. 18, 595\u2013605. https:\/\/doi.org\/10.1016\/s0022-2828(86)80967-1 (1986).","DOI":"10.1016\/s0022-2828(86)80967-1"},{"key":"43642_CR31","doi-asserted-by":"publisher","first-page":"871","DOI":"10.18433\/j3tg88","volume":"18","author":"A Kam","year":"2015","unstructured":"Kam, A., Razmovski-Naumovski, V., Zhou, X., Troung, J. & Chan, K. Nucleoside Transport Inhibition by Dipyridamole Prevents Angiogenesis Impairment by Homocysteine and Adenosine. J. Pharm. Pharm. Sci. 18, 871\u2013881. https:\/\/doi.org\/10.18433\/j3tg88 (2015).","journal-title":"J. Pharm. Pharm. Sci."},{"key":"43642_CR32","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1042\/bj2370845","volume":"237","author":"AC Newby","year":"1986","unstructured":"Newby, A. C. How does dipyridamole elevate extracellular adenosine concentration? Predictions from a three-compartment model of adenosine formation and inactivation. Biochem. J. 237, 845\u2013851. https:\/\/doi.org\/10.1042\/bj2370845 (1986).","journal-title":"Biochem. J."},{"key":"43642_CR33","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1007\/s11033-024-09382-z","volume":"51","author":"M Mahdizadeh","year":"2024","unstructured":"Mahdizadeh, M., Heydari, N., Shafiei, A., Akbari, H. & Jafari, S. M. Adenosine receptors in breast cancer. Mol. Biol. Rep. 51, 464. https:\/\/doi.org\/10.1007\/s11033-024-09382-z (2024).","journal-title":"Mol. Biol. Rep."},{"key":"43642_CR34","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1002\/jcp.27249","volume":"234","author":"A Soleimani","year":"2019","unstructured":"Soleimani, A. et al. Therapeutic potency of pharmacological adenosine receptors agonist\/antagonist on cancer cell apoptosis in tumor microenvironment, current status, and perspectives. J. Cell. Physiol. 234, 2329\u20132336. https:\/\/doi.org\/10.1002\/jcp.27249 (2019).","journal-title":"J. Cell. Physiol."},{"key":"43642_CR35","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.bbrc.2023.08.014","volume":"678","author":"Z Taghinejad","year":"2023","unstructured":"Taghinejad, Z., Kazemi, T., Fadaee, M., Farshdousti Hagh, M. & Solali, S. Pharmacological and therapeutic potentials of cordycepin in hematological malignancies. Biochem. Biophys. Res. Commun. 678, 135\u2013143. https:\/\/doi.org\/10.1016\/j.bbrc.2023.08.014 (2023).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"43642_CR36","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.molonc.2014.08.010","volume":"9","author":"AE Goda","year":"2015","unstructured":"Goda, A. E., Erikson, R. L., Sakai, T., Ahn, J. S. & Kim, B. Y. Preclinical evaluation of bortezomib\/dipyridamole novel combination as a potential therapeutic modality for hematologic malignancies. Mol. Oncol. 9, 309\u2013322. https:\/\/doi.org\/10.1016\/j.molonc.2014.08.010 (2015).","journal-title":"Mol. Oncol."},{"key":"43642_CR37","doi-asserted-by":"publisher","unstructured":"Correction to \u2018SynergyFinder 2.0: visual analytics of multi-drug combination synergies\u2019. Nucleic Acids Res 50, 7198, (2022). https:\/\/doi.org\/10.1093\/nar\/gkac552","DOI":"10.1093\/nar\/gkac552"},{"key":"43642_CR38","doi-asserted-by":"publisher","first-page":"W488","DOI":"10.1093\/nar\/gkaa216","volume":"48","author":"A Ianevski","year":"2020","unstructured":"Ianevski, A., Giri, A. K. & Aittokallio, T. SynergyFinder 2.0: visual analytics of multi-drug combination synergies. Nucleic Acids Res. 48, W488\u2013W493. https:\/\/doi.org\/10.1093\/nar\/gkaa216 (2020).","journal-title":"Nucleic Acids Res."},{"key":"43642_CR39","doi-asserted-by":"publisher","first-page":"W739","DOI":"10.1093\/nar\/gkac382","volume":"50","author":"A Ianevski","year":"2022","unstructured":"Ianevski, A., Giri, A. K. & Aittokallio, T. SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. Nucleic Acids Res. 50, W739\u2013W743. https:\/\/doi.org\/10.1093\/nar\/gkac382 (2022).","journal-title":"Nucleic Acids Res."},{"key":"43642_CR40","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1159\/000341447","volume":"30","author":"T Kanno","year":"2012","unstructured":"Kanno, T., Nakano, T., Fujita, Y., Gotoh, A. & Nishizaki, T. Adenosine induces apoptosis in SBC-3 human lung cancer cells through A(3) adenosine receptor-dependent AMID upregulation. Cell. Physiol. Biochem. 30, 666\u2013677. https:\/\/doi.org\/10.1159\/000341447 (2012).","journal-title":"Cell. Physiol. Biochem."},{"key":"43642_CR41","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1016\/j.bcp.2004.01.020","volume":"67","author":"M Saitoh","year":"2004","unstructured":"Saitoh, M. et al. Adenosine induces apoptosis in the human gastric cancer cells via an intrinsic pathway relevant to activation of AMP-activated protein kinase. Biochem. Pharmacol. 67, 2005\u20132011. https:\/\/doi.org\/10.1016\/j.bcp.2004.01.020 (2004).","journal-title":"Biochem. Pharmacol."},{"key":"43642_CR42","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s00535-008-2273-7","volume":"44","author":"Y Yasuda","year":"2009","unstructured":"Yasuda, Y., Saito, M., Yamamura, T., Yaguchi, T. & Nishizaki, T. Extracellular adenosine induces apoptosis in Caco-2 human colonic cancer cells by activating caspase-9\/-3 via A(2a) adenosine receptors. J. Gastroenterol. 44, 56\u201365. https:\/\/doi.org\/10.1007\/s00535-008-2273-7 (2009).","journal-title":"J. Gastroenterol."},{"key":"43642_CR43","doi-asserted-by":"publisher","first-page":"3994","DOI":"10.1021\/jm900413e","volume":"52","author":"T Borrmann","year":"2009","unstructured":"Borrmann, T. et al. 1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with subnanomolar affinity and subtype specificity. J. Med. Chem. 52, 3994\u20134006. https:\/\/doi.org\/10.1021\/jm900413e (2009).","journal-title":"J. Med. Chem."},{"key":"43642_CR44","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/0024-3205(87)90369-9","volume":"40","author":"SJ Haleen","year":"1987","unstructured":"Haleen, S. J., Steffen, R. P. & Hamilton, H. W. PD 116,948, a highly selective A1 adenosine receptor antagonist. Life Sci. 40, 555\u2013561. https:\/\/doi.org\/10.1016\/0024-3205(87)90369-9 (1987).","journal-title":"Life Sci."},{"key":"43642_CR45","doi-asserted-by":"publisher","first-page":"3186","DOI":"10.1021\/jm980093j","volume":"41","author":"AH Li","year":"1998","unstructured":"Li, A. H., Moro, S., Melman, N., Ji, X. D. & Jacobson, K. A. Structure-activity relationships and molecular modeling of 3, 5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. J. Med. Chem. 41, 3186\u20133201. https:\/\/doi.org\/10.1021\/jm980093j (1998).","journal-title":"J. Med. Chem."},{"key":"43642_CR46","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1111\/j.1476-5381.1995.tb15923.x","volume":"115","author":"SM Poucher","year":"1995","unstructured":"Poucher, S. M. et al. The in vitro pharmacology of ZM 241385, a potent, non-xanthine A2a selective adenosine receptor antagonist. Br. J. Pharmacol. 115, 1096\u20131102. https:\/\/doi.org\/10.1111\/j.1476-5381.1995.tb15923.x (1995).","journal-title":"Br. J. Pharmacol."},{"key":"43642_CR47","doi-asserted-by":"publisher","first-page":"11448","DOI":"10.1021\/acs.jmedchem.0c00525","volume":"63","author":"KV Lawson","year":"2020","unstructured":"Lawson, K. V. et al. Discovery of AB680: A Potent and Selective Inhibitor of CD73. J. Med. Chem. 63, 11448\u201311468. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c00525 (2020).","journal-title":"J. Med. Chem."},{"key":"43642_CR48","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","volume":"378","author":"CS Tam","year":"2018","unstructured":"Tam, C. S. et al. Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma. N. Engl. J. Med. 378, 1211\u20131223. https:\/\/doi.org\/10.1056\/NEJMoa1715519 (2018).","journal-title":"N Engl. J. Med."},{"key":"43642_CR49","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1182\/blood.2022019332","volume":"141","author":"CRM Bangham","year":"2023","unstructured":"Bangham, C. R. M. HTLV-1 persistence and the oncogenesis of adult T-cell leukemia\/lymphoma. Blood 141, 2299\u20132306. https:\/\/doi.org\/10.1182\/blood.2022019332 (2023).","journal-title":"Blood"},{"key":"43642_CR50","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1111\/cas.13303","volume":"108","author":"Y Kogure","year":"2017","unstructured":"Kogure, Y. & Kataoka, K. Genetic alterations in adult T-cell leukemia\/lymphoma. Cancer Sci. 108, 1719\u20131725. https:\/\/doi.org\/10.1111\/cas.13303 (2017).","journal-title":"Cancer Sci."},{"key":"43642_CR51","doi-asserted-by":"publisher","unstructured":"Yamagishi, M., Suzuki, Y., Watanabe, T. & Uchimaru, K. Clonal Selection and Evolution of HTLV-1-Infected Cells Driven by Genetic and Epigenetic Alteration. Viruses 14, (2022). https:\/\/doi.org\/10.3390\/v14030587","DOI":"10.3390\/v14030587"},{"key":"43642_CR52","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/s0092-8674(00)81683-9","volume":"100","author":"D Hanahan","year":"2000","unstructured":"Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57\u201370. https:\/\/doi.org\/10.1016\/s0092-8674(00)81683-9 (2000).","journal-title":"Cell"},{"key":"43642_CR53","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013 (2011).","journal-title":"Cell"},{"key":"43642_CR54","doi-asserted-by":"publisher","first-page":"108300","DOI":"10.1016\/j.pharmthera.2022.108300","volume":"240","author":"T Kaur","year":"2022","unstructured":"Kaur, T. et al. Nucleoside transporters and immunosuppressive adenosine signaling in the tumor microenvironment: Potential therapeutic opportunities. Pharmacol. Ther. 240, 108300. https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108300 (2022).","journal-title":"Pharmacol. Ther."},{"key":"43642_CR55","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1124\/pharmrev.121.000528","volume":"74","author":"GG Yegutkin","year":"2022","unstructured":"Yegutkin, G. G. & Boison, D. ATP and Adenosine Metabolism in Cancer: Exploitation for Therapeutic Gain. Pharmacol. Rev. 74, 797\u2013822. https:\/\/doi.org\/10.1124\/pharmrev.121.000528 (2022).","journal-title":"Pharmacol. Rev."},{"key":"43642_CR56","doi-asserted-by":"publisher","unstructured":"Chiou, J. et al. Targeting Metabolic and Epigenetic Vulnerabilities in Glioblastoma with SN-38 and Rabusertib Combination Therapy. Int. J. Mol. Sci. 26 https:\/\/doi.org\/10.3390\/ijms26020474 (2025).","DOI":"10.3390\/ijms26020474"},{"key":"43642_CR57","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1002\/cac2.12374","volume":"42","author":"T Ge","year":"2022","unstructured":"Ge, T. et al. Crosstalk between metabolic reprogramming and epigenetics in cancer: updates on mechanisms and therapeutic opportunities. Cancer Commun. 42, 1049\u20131082. https:\/\/doi.org\/10.1002\/cac2.12374 (2022).","journal-title":"Cancer Commun."},{"key":"43642_CR58","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s12672-024-01195-7","volume":"15","author":"DC Joshi","year":"2024","unstructured":"Joshi, D. C. et al. Novel therapeutic agents in clinical trials: emerging approaches in cancer therapy. Discov. Oncol. 15, 342. https:\/\/doi.org\/10.1007\/s12672-024-01195-7 (2024).","journal-title":"Discov. Oncol."},{"key":"43642_CR59","doi-asserted-by":"publisher","unstructured":"Xing, J., Zhang, J. & Wang, J. The Immune Regulatory Role of Adenosine in the Tumor Microenvironment. Int. J. Mol. Sci. 24 https:\/\/doi.org\/10.3390\/ijms241914928 (2023).","DOI":"10.3390\/ijms241914928"},{"key":"43642_CR60","doi-asserted-by":"publisher","unstructured":"Jenke, R., Ressing, N., Hansen, F. K., Aigner, A. & Buch, T. Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives. Cancers. https:\/\/doi.org\/10.3390\/cancers13040634 (2021).","DOI":"10.3390\/cancers13040634"},{"key":"43642_CR61","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1091\/mbc.E14-01-0042","volume":"25","author":"A Mello Pde","year":"2014","unstructured":"Mello Pde, A. et al. Adenosine uptake is the major effector of extracellular ATP toxicity in human cervical cancer cells. Mol. Biol. Cell. 25, 2905\u20132918. https:\/\/doi.org\/10.1091\/mbc.E14-01-0042 (2014).","journal-title":"Mol. Biol. Cell."},{"key":"43642_CR62","doi-asserted-by":"publisher","first-page":"107057","DOI":"10.1016\/j.ejps.2025.107057","volume":"208","author":"N El Omari","year":"2025","unstructured":"El Omari, N. et al. Clinical efficacy and mechanistic insights of FDA-approved HDAC inhibitors in the treatment of lymphoma. Eur. J. Pharm. Sci. 208, 107057. https:\/\/doi.org\/10.1016\/j.ejps.2025.107057 (2025).","journal-title":"Eur. J. Pharm. Sci."},{"key":"43642_CR63","doi-asserted-by":"publisher","first-page":"424","DOI":"10.7150\/ijms.30154","volume":"16","author":"Q Zhang","year":"2019","unstructured":"Zhang, Q., Wang, S., Chen, J. & Yu, Z. Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas. Int. J. Med. Sci. 16, 424\u2013442. https:\/\/doi.org\/10.7150\/ijms.30154 (2019).","journal-title":"Int. J. Med. Sci."},{"key":"43642_CR64","doi-asserted-by":"publisher","first-page":"6844","DOI":"10.3748\/wjg.v27.i40.6844","volume":"27","author":"CJ Carter","year":"2021","unstructured":"Carter, C. J., Mekkawy, A. H. & Morris, D. L. Role of human nucleoside transporters in pancreatic cancer and chemoresistance. World J. Gastroenterol. 27, 6844\u20136860. https:\/\/doi.org\/10.3748\/wjg.v27.i40.6844 (2021).","journal-title":"World J. Gastroenterol."},{"key":"43642_CR65","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.14670\/HH-18-881","volume":"40","author":"M McKenna","year":"2025","unstructured":"McKenna, M. et al. Human equilibrative nucleoside transporter 1 and concentrative nucleoside transporter 1 in colorectal cancer: What do we know? A systematic review. Histol. Histopathol. 40, 1153\u20131162. https:\/\/doi.org\/10.14670\/HH-18-881 (2025).","journal-title":"Histol. Histopathol"},{"key":"43642_CR66","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/sj.leu.2403271","volume":"18","author":"M Pastor-Anglada","year":"2004","unstructured":"Pastor-Anglada, M. et al. Nucleoside transporters in chronic lymphocytic leukaemia. Leukemia 18, 385\u2013393. https:\/\/doi.org\/10.1038\/sj.leu.2403271 (2004).","journal-title":"Leukemia"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43642-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43642-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43642-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:08:21Z","timestamp":1781640501000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43642-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,15]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["43642"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-43642-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,15]]},"assertion":[{"value":"12 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13570"}}